Literature DB >> 21596616

Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma.

Meltem Ekenel1, Serkan Keskin, Mert Basaran, Canan Ozdemir, Rasim Meral, Musa Altun, Ismet Aslan, Sevil E Bavbek.   

Abstract

Radiotherapy (RT) with concomitant chemotherapy (CT) has improved the therapeutic outcome of patients with locally advanced nasopharyngeal carcinoma (LANC). However, the importance of induction CT before definitive therapy is still undefined. Patients (n=59) who had LANC were included in this retrospective study. They received induction CT consisting of cisplatin and docetaxel followed by definitive RT with cisplatin. The median age was 49 years (18-68). All patients were of stages II (15%), III (63%) and IV (22%). Fifty eight patients could receive 3 cycles of CT. Except one patient, there was no grade 3 or 4 toxicity during induction CT. Chemoradiotherapy could be given to 49 patients (83%). Twelve percent of patients had complete response after induction CT and this number had increased to 95% after the completion of the therapy. Objective responses (complete and partial) were 100% after the completion of the therapy. Median follow up time was 29 months. Nine patients had relapse (2 had local only, 4 distant, 3 local and distant). Three patients who had both local and distant relapse died during follow-up. Three year overall and progression free survival rates were 94.9% and 84.7%, respectively. Induction CT with docetaxel and cisplatin is a feasible and tolerable treatment for patients with LANC.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596616     DOI: 10.1016/j.oraloncology.2011.04.010

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  8 in total

1.  Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.

Authors:  Ting Jin; Xiao-Zhong Chen; Jian-Jiang Liu
Journal:  Oncol Lett       Date:  2015-06-10       Impact factor: 2.967

2.  The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma.

Authors:  Lei Zhang; Guo-ping Shan; Pu Li; Ping-jing Cheng
Journal:  Med Oncol       Date:  2015-01-29       Impact factor: 3.064

3.  Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas.

Authors:  Francesco Perri; Giuseppina Della Vittoria Scarpati; Carlo Buonerba; Giuseppe Di Lorenzo; Francesco Longo; Paolo Muto; Concetta Schiavone; Fabio Sandomenico; Francesco Caponigro
Journal:  World J Clin Oncol       Date:  2013-05-10

Review 4.  The roles of ribosomal proteins in nasopharyngeal cancer: culprits, sentinels or both.

Authors:  Edmund Ui-Hang Sim; Choon-Weng Lee; Kumaran Narayanan
Journal:  Biomark Res       Date:  2021-06-30

5.  Is Gemcitabine and Cisplatin Induction Chemotherapy Superior in Locoregionally Advanced Nasopharyngeal Carcinoma?

Authors:  Wei Zheng; Sufang Qiu; Lingling Huang; Jianji Pan
Journal:  Pak J Med Sci       Date:  2015 Jul-Aug       Impact factor: 1.088

6.  The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.

Authors:  Jin Ho Song; Hong-Gyun Wu; Bhum Suk Keam; Jeong Hun Hah; Yong Chan Ahn; Dongryul Oh; Jae Myoung Noh; Hyo Jung Park; Chang Geol Lee; Ki Chang Keum; Jihye Cha; Kwan Ho Cho; Sung Ho Moon; Ji-Yoon Kim; Woong-Ki Chung; Young Taek Oh; Won Taek Kim; Moon-June Cho; Chul Seung Kay; Yeon-Sil Kim
Journal:  Cancer Res Treat       Date:  2015-12-28       Impact factor: 4.679

7.  Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Authors:  Ting Jin; Wei-Feng Qin; Feng Jiang; Qi-Feng Jin; Qi-Chun Wei; Yong-Shi Jia; Xiao-Nan Sun; Wen-Feng Li; Xiao-Zhong Chen
Journal:  Transl Oncol       Date:  2019-02-20       Impact factor: 4.243

8.  NACT+IMRT versus NACT+IMRT+CCRT in locoregionally advanced NPC patients: a retrospective study.

Authors:  Xialin Chen; Xiang Zhu; Jianfang Wang; Jianjiang Liu; Rong Ji
Journal:  Onco Targets Ther       Date:  2019-02-22       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.